Published in J Immunother on September 14, 2006
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines (2014) 0.79
HIV-Specific CD8(+) T Lymphocytes in Blood of Long-Term HIV-Infected Hemophilia Patients. Biores Open Access (2013) 0.75
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif (2003) 4.68
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis (2007) 3.80
Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol (2007) 3.05
Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol (2004) 2.30
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol (2005) 2.25
The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol (2005) 2.17
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS (2005) 1.99
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol (2008) 1.75
Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis (2006) 1.68
Knowledge, health seeking behavior and perceived stigma towards tuberculosis among tuberculosis suspects in a rural community in southwest Ethiopia. PLoS One (2010) 1.63
Tuberculosis and HIV co-infection: its impact on quality of life. Health Qual Life Outcomes (2009) 1.62
Cell cycle and apoptosis. Cell Prolif (2003) 1.59
Differential effect of jasmonic acid and abscisic acid on cell cycle progression in tobacco BY-2 cells. Plant Physiol (2002) 1.58
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother (2004) 1.54
Neuroglobin and cytoglobin overexpression protects human SH-SY5Y neuroblastoma cells against oxidative stress-induced cell death. Neurosci Lett (2006) 1.50
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47
Apoptosis: mechanisms and relevance in cancer. Ann Hematol (2005) 1.44
Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol (2007) 1.44
Common mental disorders in TB/HIV co-infected patients in Ethiopia. BMC Infect Dis (2010) 1.41
CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother (2008) 1.40
mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther (2007) 1.40
The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology (2006) 1.33
Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev (2010) 1.17
Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol (2006) 1.16
Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol (2009) 1.12
Regulatory T cells and human disease. Clin Dev Immunol (2007) 1.12
Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS (2006) 1.10
Relatively low primary drug resistant tuberculosis in southwestern Ethiopia. BMC Res Notes (2012) 1.10
Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy (2009) 1.09
Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS One (2011) 1.09
Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08
mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J Cell Mol Med (2007) 1.08
Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One (2012) 1.08
Tuberculosis drug resistance testing by molecular methods: opportunities and challenges in resource limited settings. J Microbiol Methods (2010) 1.07
MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. PLoS Pathog (2012) 1.07
HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon. J Acquir Immune Defic Syndr (2002) 1.07
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist (2012) 1.07
The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. PLoS One (2013) 1.05
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med (2009) 1.05
Prejudice and misconceptions about tuberculosis and HIV in rural and urban communities in Ethiopia: a challenge for the TB/HIV control program. BMC Public Health (2010) 1.05
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04
The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein. Eur J Hum Genet (2011) 1.03
Dendritic cell-based cancer gene therapy. Hum Gene Ther (2009) 1.02
Quantification of circulating endothelial progenitor cells: a methodological comparison of six flow cytometric approaches. J Immunol Methods (2008) 1.01
Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther (2012) 1.01
Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets (2004) 1.01
Increased caspase activation and decreased TDP-43 solubility in progranulin knockout cortical cultures. J Neurochem (2010) 1.00
SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness. J Neurovirol (2006) 1.00
Predominance of infection with HIV-1 circulating recombinant form CRF02_AG in major Cameroonian cities and towns. AIDS (2002) 0.99
Transcriptome analysis of monocyte-HIV interactions. Retrovirology (2010) 0.98
Prevalence of pulmonary TB and spoligotype pattern of Mycobacterium tuberculosis among TB suspects in a rural community in Southwest Ethiopia. BMC Infect Dis (2012) 0.98
Clinical potential of intravenous neural stem cell delivery for treatment of neuroinflammatory disease in mice? Cell Transplant (2010) 0.98
Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. BMC Biotechnol (2009) 0.98
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood (2005) 0.98
A maximal exercise bout increases the number of circulating CD34+/KDR+ endothelial progenitor cells in healthy subjects. Relation with lipid profile. J Appl Physiol (1985) (2008) 0.97
Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev (2014) 0.97
The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother (2009) 0.97
A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antiviral Res (2006) 0.97
Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS (2002) 0.96
Current challenges for the advancement of neural stem cell biology and transplantation research. Stem Cell Rev (2012) 0.96
Decreased number of circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary artery disease. Coron Artery Dis (2006) 0.96
When hymenopteran males reinvented diploidy. Curr Biol (2005) 0.96
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res (2013) 0.96